Avalo Therapeutics, Inc. (AVTX): who owns it and who trades it
As of Nov 16, 2026, AVTX insiders reported 41 open-market sales worth $8.3M and no purchases in the last 12 months, with 99% of the sale value made under pre-set 10b5-1 plans. The largest seller was Christopher Ryan Sullivan (CFO), with $3.7M. 5 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling Avalo Therapeutics
From the latest filingsOverall: about as much buying as selling. Insiders mostly sold. Funds and famous investors mostly bought.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Who owns AVTX
127 funds and institutions reported AVTX shares worth $1.3B at the end of Q2 2026. The largest holder is FMR LLC (Fidelity) with $94.3M.
10 largest owners, by value
Top 20 owners
| Owner | Shares | % of company | Value | Change since Q1 2026 |
|---|---|---|---|---|
| FMR LLC (Fidelity) | 5.10M | – | $94.3M | +77% |
| BlackRock, Inc. | 4.37M | – | $80.7M | +1235% |
| Nantahala Capital Management, LLC | 3.72M | – | $68.8M | +202% |
| Deep Track Capital, LP | 3.61M | – | $66.7M | New |
| Caligan Partners LP | 3.16M | – | $58.5M | +94% |
| TCG Crossover Management, LLC | 3.02M | – | $55.8M | +309% |
| Affinity Asset Advisors, LLC | 2.90M | – | $53.6M | +116% |
| State Street Corp | 2.89M | – | $53.4M | +3932% |
| Farallon Capital Management, L.l.c. | 2.50M | – | $46.2M | +173% |
| Point72 Asset Management, L.P. | 2.39M | – | $44.1M | +161% |
| Avoro Capital Advisors LLC | 2.33M | – | $43.1M | +65% |
| Vanguard Capital Management LLC | 2.26M | – | $41.8M | +215% |
| Bvf Inc | 2.08M | – | $38.4M | +27% |
| Bank of America Corp | 1.91M | – | $35.4M | +198% |
| Adage Capital Partners Gp, L.l.c. | 1.73M | – | $32M | +102% |
| Soleus Capital Management, L.P. | 1.65M | – | $30.6M | +274% |
| Braidwell LP | 1.63M | – | $30.1M | New |
| T. Rowe Price Associates | 1.31M | – | $24.2M | New |
| Alliancebernstein L.P. | 1.26M | – | $23.3M | New |
| UBS Group AG | 1.21M | – | $22.3M | +6% |
From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.
Insider trades
In the last 12 months, AVTX insiders reported $0 of open-market purchases and $8.3M of sales. 99% of the sale value was under a 10b5-1 plan, a schedule set up in advance.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Sep 16, 2026 | Christopher Ryan Sullivan | CFO | Sale plan | 12,394 | $16.33 | $202K | Form 4 |
| Sep 10, 2026 | Christopher Ryan Sullivan | CFO | Sale plan | 10,185 | $17.62 | $179K | Form 4 |
| Aug 28, 2026 | Mittie Doyle | Chief Medical Officer | Sale plan | 679 | $20.00 | $13.6K | Form 4 |
| Aug 18, 2026 | Christopher Ryan Sullivan | CFO | Sale plan | 31,031 | $20.05 | $622K | Form 4 |
| Aug 17, 2026 | Christopher Ryan Sullivan | CFO | Sale plan | 3,749 | $19.94 | $74.8K | Form 4 |
| Aug 17, 2026 | Christopher Ryan Sullivan | CFO | Sale plan | 37,945 | $19.85 | $753K | Form 4 |
| Aug 17, 2026 | Mittie Doyle | Chief Medical Officer | Sale plan | 1,000 | $20.00 | $20K | Form 4 |
| Aug 11, 2026 | Jennifer Riley | Chief Strategy Officer | Sale | 2,655 | $19.59 | $52K | Form 4 |
| Aug 10, 2026 | Mittie Doyle | Chief Medical Officer | Sale plan | 679 | $20.00 | $13.6K | Form 4 |
| Jul 27, 2026 | Mittie Doyle | Chief Medical Officer | Sale plan | 1,000 | $20.00 | $20K | Form 4 |
| Jun 30, 2026 | Mittie Doyle | Chief Medical Officer | Sale plan | 4,654 | $20.00 | $93.1K | Form 4 |
| Jun 23, 2026 | Mittie Doyle | Chief Medical Officer | Sale plan | 1,450 | $18.00 | $26.1K | Form 4 |
| May 28, 2026 | Mittie Doyle | Chief Medical Officer | Sale plan | 679 | $16.00 | $10.9K | Form 4 |
| May 15, 2026 | Mittie Doyle | Chief Medical Officer | Sale plan | 3,000 | $18.76 | $56.3K | Form 4 |
| May 7, 2026 | Christopher Ryan Sullivan | CFO | Sale plan | 18,606 | $24.12 | $449K | Form 4 |
| May 6, 2026 | Paul Varki | Chief Legal Officer | Sale plan | 37,375 | $18.91 | $707K | Form 4 |
| May 6, 2026 | Paul Varki | Chief Legal Officer | Sale plan | 5,196 | $19.78 | $103K | Form 4 |
| May 6, 2026 | Paul Varki | Chief Legal Officer | Sale plan | 9,253 | $22.70 | $210K | Form 4 |
| May 6, 2026 | Paul Varki | Chief Legal Officer | Sale plan | 400 | $23.71 | $9.5K | Form 4 |
| May 6, 2026 | Paul Varki | Chief Legal Officer | Sale plan | 22,839 | $21.22 | $485K | Form 4 |
| May 6, 2026 | Christopher Ryan Sullivan | CFO | Sale plan | 9,219 | $21.37 | $197K | Form 4 |
| May 6, 2026 | Christopher Ryan Sullivan | CFO | Sale plan | 2,700 | $20.76 | $56.1K | Form 4 |
| May 6, 2026 | Christopher Ryan Sullivan | CFO | Sale plan | 12,347 | $19.28 | $238K | Form 4 |
| May 6, 2026 | Christopher Ryan Sullivan | CFO | Sale plan | 8,900 | $22.57 | $201K | Form 4 |
| May 6, 2026 | Christopher Ryan Sullivan | CFO | Sale plan | 13,834 | $18.55 | $257K | Form 4 |
| May 6, 2026 | Mittie Doyle | Chief Medical Officer | Sale plan | 19,015 | $22.41 | $426K | Form 4 |
| May 6, 2026 | Mittie Doyle | Chief Medical Officer | Sale plan | 44,944 | $21.20 | $953K | Form 4 |
| May 6, 2026 | Mittie Doyle | Chief Medical Officer | Sale plan | 5,000 | $19.65 | $98.2K | Form 4 |
| May 6, 2026 | Mittie Doyle | Chief Medical Officer | Sale plan | 27,538 | $18.03 | $497K | Form 4 |
| May 6, 2026 | Mittie Doyle | Chief Medical Officer | Sale plan | 10,058 | $22.88 | $230K | Form 4 |
| May 6, 2026 | Mitchell Chan | Director | Sale plan | 3,167 | $22.88 | $72.5K | Form 4 |
| May 5, 2026 | Mittie Doyle | Chief Medical Officer | Sale plan | 1,679 | $16.00 | $26.9K | Form 4 |
| Apr 30, 2026 | Christopher Ryan Sullivan | CFO | Sale plan | 8,457 | $13.23 | $112K | Form 4 |
| Apr 29, 2026 | Christopher Ryan Sullivan | CFO | Sale plan | 8,458 | $13.09 | $111K | Form 4 |
| Apr 6, 2026 | Mittie Doyle | Chief Medical Officer | Sale plan | 3,970 | $18.01 | $71.5K | Form 4 |
| Apr 2, 2026 | Christopher Ryan Sullivan | CFO | Sale plan | 1,780 | $17.57 | $31.3K | Form 4 |
| Apr 2, 2026 | Christopher Ryan Sullivan | CFO | Sale plan | 6,200 | $17.02 | $106K | Form 4 |
| Apr 1, 2026 | Christopher Ryan Sullivan | CFO | Sale plan | 7,479 | $16.83 | $126K | Form 4 |
| Apr 1, 2026 | Christopher Ryan Sullivan | CFO | Sale plan | 500 | $15.86 | $7.9K | Form 4 |
| Apr 1, 2026 | Mittie Doyle | Chief Medical Officer | Sale plan | 679 | $16.00 | $10.9K | Form 4 |
| Mar 16, 2026 | Mittie Doyle | Chief Medical Officer | Sale plan | 25,492 | $16.15 | $412K | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| Christopher Ryan Sullivan | Chief Financial Officer | – | $3.7M | Sep 16, 2026 |
| Mittie Doyle | Chief Medical Officer | – | $3M | Aug 28, 2026 |
| Paul Varki | Chief Legal Officer | – | $1.5M | May 6, 2026 |
| Mitchell Chan | Director | – | $72.5K | May 6, 2026 |
| Jennifer Riley | Chief Strategy Officer | – | $52K | Aug 11, 2026 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
AVTX short interest
High short interest. 16.6% of AVTX shares are sold short: about 1 share in 6. Over the last 12 reports the number of shares short went up 42%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 8.91M AVTX shares were sold short, 16.6% of the shares outstanding, down 25.5% from the report before. At the average daily volume of 4.26M shares, buying them all back would take about 2.1 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 8.91M | 16.62% | -26% | 4.26M | 2.1 |
| Oct 15, 2026 | 11.96M | 22.31% | +5% | 919,676 | 13.0 |
| Sep 30, 2026 | 11.41M | 21.27% | -12% | 1.30M | 8.8 |
| Sep 15, 2026 | 12.93M | 24.10% | +4% | 976,376 | 13.2 |
| Aug 31, 2026 | 12.39M | 23.10% | -5% | 816,596 | 15.2 |
| Aug 14, 2026 | 13.09M | 24.41% | +1% | 647,143 | 20.2 |
| Jul 31, 2026 | 12.95M | 56.83% | +2% | 900,454 | 14.4 |
| Jul 15, 2026 | 12.68M | 55.64% | +3% | 1.19M | 10.7 |
| Jun 30, 2026 | 12.31M | 54.01% | +66% | 2.89M | 4.3 |
| Jun 15, 2026 | 7.41M | 32.53% | +16% | 1.34M | 5.5 |
| May 29, 2026 | 6.38M | 28.01% | +2% | 1.46M | 4.4 |
| May 15, 2026 | 6.25M | 27.44% | +9% | 3.94M | 1.6 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Avalo Therapeutics company events
Avalo Therapeutics filed 15 reports on Form 8-K in the last 12 months, 4 of them about an important change (leadership). The latest was on Nov 5, 2026.
- Nov 5, 2026AgreementAvalo Therapeutics, Inc. entered into an Open Market Sale Agreement SM, with Jefferies LLC with respect to an “at-the-market” offering program under which the Company may issue and sell, from time to time at the Company’s sole discretion, shares of the Company’s common stock, $0.001 par value per… Filing
- Nov 5, 2026ResultsReleased financial results. Filing
- Aug 6, 2026ResultsReleased financial results. Filing
- Jun 23, 2026LeadershipThe board of directors of Avalo Therapeutics, Inc. appointed Ron Philip to the Board, effective June 23, 2026. Filing
- Jun 16, 2026AnnouncementAvalo Therapeutics, Inc. issued a press release announcing the advancement of AVTX-010, a long-acting next-generation anti-IL-1β monoclonal antibody (mAb) with the potential for development in hidradenitis suppurativa (HS) as well as additional inflammatory disorders. Filing
- Jun 12, 2026LeadershipThe Company entered into amendments to employment agreements with Garry A. Neil, M.D., the Company’s Chief Executive Officer, Christopher Sullivan, the Company’s Chief Financial Officer, Mittie Doyle, M.D., FACR, the Company’s Chief Medical Officer and Taylor Boyd, Chief Business Officer (together… Filing
- Jun 8, 2026LeadershipEquity Plan Amendments As noted in Item 5.07 below, at the Avalo Therapeutics, Inc. 2026 annual meeting of stockholders, the Company’s stockholders approved the Avalo Therapeutics, Inc. Second Amended and Restated 2016 Employee Stock Purchase Plan. Filing
- May 13, 2026ResultsReleased financial results. Filing
- May 7, 2026AgreementAvalo Therapeutics, Inc. entered into an underwriting agreement with Leerink Partners LLC, TD Securities (USA) LLC and BofA Securities, Inc., as representatives of the underwriters listed in Schedule A thereto, pursuant to which the Company agreed to issue and sell an aggregate of (a) 19,730,000… Filing
- May 5, 2026AnnouncementAvalo Therapeutics, Inc. issued a press release announcing positive topline results from its Phase 2 LOTUS trial evaluating the efficacy, safety and tolerability of abdakibart in patients with moderate to severe hidradenitis suppurativa. Filing
- Apr 28, 2026AgreementAvalo Therapeutics, Inc. entered into a Milestone Buyout Option Agreement and Amendment to Agreement and Plan of Merger and Reorganization. Filing
- Mar 27, 2026LeadershipDeparture of Directors or Certain Officers; Election of Directors. Filing
- Mar 23, 2026ResultsReleased financial results. Filing
- Jan 12, 2026AnnouncementThe Company has posted on its website an updated investor presentation. Filing
- Dec 2, 2025AnnouncementAvalo Therapeutics, Inc. posted on its website an updated investor presentation. Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Avalo Therapeutics financials
Famous investors that hold AVTX
5 of the 50 well-known investors we track reported holding AVTX in their latest 13F filing. The largest position is Steve Cohen's, worth $24.9M.
Position size
All holders
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Steve Cohen · Point72 Asset Management | Q3 2026 | 1.63M | $24.9M | 0.0% | -32% |
| Ken Griffin · Citadel Advisors | Q3 2026 | 371,216 | $5.7M | 0.0% | +15% |
| Ken Fisher · Fisher Asset Management | Q3 2026 | 316,505 | $4.9M | 0.0% | New |
| Israel Englander · Millennium Management | Q3 2026 | 227,290 | $3.5M | 0.0% | New |
| Jim Simons · Renaissance Technologies | Q3 2026 | 71,979 | $1.1M | 0.0% | -80% |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
5%+ stakes filed in the last 120 days
Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 14 filings named AVTX in the last 120 days.
| Filed | Holder | Form | Stake |
|---|---|---|---|
| Nov 16, 2026 | Point72 Asset Management, L.P. | 13G/A | 3.0% |
| Nov 16, 2026 | BIOTECHNOLOGY VALUE FUND L P | 13G/A | 0.9% |
| Nov 16, 2026 | BIOTECHNOLOGY VALUE FUND L P | 13G/A | 0.9% |
| Nov 16, 2026 | Point72 Asset Management, L.P. | 13G/A | 3.0% |
| Nov 13, 2026 | Farallon Capital Management, L.L.C. | 13G | 7.4% |
| Nov 13, 2026 | Farallon Capital Management, L.L.C. | 13G | 7.4% |
| Nov 10, 2026 | STATE STREET CORPORATION | 13G | 4.8% |
| Nov 10, 2026 | STATE STREET CORPORATION | 13G | 4.8% |
| Nov 6, 2026 | FMR LLC | 13G/A | 0.9% |
| Nov 6, 2026 | FMR LLC | 13G/A | 0.9% |
| Nov 5, 2026 | FMR LLC | 13G/A | 9.8% |
| Nov 5, 2026 | FMR LLC | 13G/A | 9.8% |
| Oct 29, 2026 | Trails Edge Capital Partners, LP | 13G | 5.2% |
| Oct 29, 2026 | Trails Edge Capital Partners, LP | 13G | 5.2% |
Questions about Avalo Therapeutics, Inc. (AVTX) stock
Who owns the most AVTX stock?
The largest reported owner of Avalo Therapeutics, Inc. (AVTX) is FMR LLC (Fidelity). In total, 127 funds and institutions reported holding AVTX at the end of Q2 2026. See the largest owners.
Are AVTX insiders buying or selling?
In the last 12 months, AVTX insiders reported no open-market purchases and 41 sales worth $8.3M. The latest trade was on Sep 16, 2026. See every trade.
What is the short interest in AVTX?
As of Oct 30, 2026, 8.91M AVTX shares were sold short, 16.6% of the shares outstanding, down 25.5% from the report before. At the average daily volume of 4.26M shares, buying them all back would take about 2.1 trading days (days to cover). See the history.
Which famous investors hold AVTX?
5 of the 50 well-known investors we track reported AVTX in their latest 13F filing, including Steve Cohen, Ken Griffin, Ken Fisher. The largest position is worth $24.9M. See all holders.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.